These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 2219400)
1. Mechanism of rejection of MHC class I-disparate murine skin grafts--histological and immunohistochemical studies of the rejection phenomenon. Kobayashi E; Kawai K; Ito M; Matsumoto Y; Fujiwara M Transplant Proc; 1990 Oct; 22(5):2352-7. PubMed ID: 2219400 [No Abstract] [Full Text] [Related]
2. Mechanism of rejection of MHC class I-disparate murine skin grafts. II. Adoptive cell transfer experiments and immunohistochemical studies. Kobayashi E; Kawai K; Ikarashi Y; Watanabe H; Ito M; Fujiwara M Transplant Proc; 1991 Jun; 23(3):2005-7. PubMed ID: 2063472 [No Abstract] [Full Text] [Related]
3. Mechanism of rejection of MHC class II-disparate murine skin grafts. I. Immunohistochemical analysis of T-cell subsets infiltrating the site of the graft. Kobayashi E; Fujiwara M Transplant Proc; 1992 Feb; 24(1):419-22. PubMed ID: 1531715 [No Abstract] [Full Text] [Related]
4. Adoptively transferred CD4+ lymphocytes from CD8 -/- mice are sufficient to mediate the rejection of MHC class II or class I disparate skin grafts. Dalloul AH; Chmouzis E; Ngo K; Fung-Leung WP J Immunol; 1996 Jun; 156(11):4114-9. PubMed ID: 8666777 [TBL] [Abstract][Full Text] [Related]
5. The T cell populations mediating rejection of MHC class I disparate skin grafts in mice. Rosenberg AS Transpl Immunol; 1993; 1(2):93-9. PubMed ID: 7915953 [No Abstract] [Full Text] [Related]
6. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. Le Moine A; Surquin M; Demoor FX; Noël JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D J Immunol; 1999 Oct; 163(7):3778-84. PubMed ID: 10490975 [TBL] [Abstract][Full Text] [Related]
7. Mechanism of rejection of MHC class I-disparate murine skin grafts. III. Are L3T4+ T cells involved in the rejection? Kobayashi E; Kawai K; Ikarashi Y; Watanabe H; Ito M; Fujiwara M Transplant Proc; 1991 Jun; 23(3):2008-11. PubMed ID: 1676551 [No Abstract] [Full Text] [Related]
8. Evidence that a "four-cell cluster" may prime cytotoxic T-cells during graft rejection. Lee R; Glimcher LH; Auchincloss H Transplant Proc; 1993 Feb; 25(1 Pt 2):847-9. PubMed ID: 8442245 [No Abstract] [Full Text] [Related]
9. Involvement of Th2-like T cells in regulating allograft reactivity against MHC class II-disparate antigen. Maeda H; Ogoshi S; Fujimoto S Transplant Proc; 1994 Apr; 26(2):847-8. PubMed ID: 8171685 [No Abstract] [Full Text] [Related]
10. An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection. Haskova Z; Sproule TJ; Roopenian DC; Ksander AB Transplantation; 2003 Apr; 75(8):1368-74. PubMed ID: 12717232 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of the rejection of major histocompatibility complex class I-disparate murine skin grafts: rejection can be mediated by CD4+ cells activated by allo-class I + II antigen in CD8+ cell-depleted hosts. Kobayashi E; Kawai K; Ikarashi Y; Fujiwara M J Exp Med; 1992 Aug; 176(2):617-21. PubMed ID: 1354244 [TBL] [Abstract][Full Text] [Related]
12. Effector cells must recognize antigens expressed in the graft to cause efficient skin graft rejection in SCID mice. Wecker H; Grusby MJ; Auchincloss H Transplantation; 1995 Apr; 59(8):1223-7. PubMed ID: 7732570 [No Abstract] [Full Text] [Related]
13. Adoptive immunity in immune-deficient scid/scid mice. I. Differential requirements of naive and primed lymphocytes for CD4+ T cells during rejection of minor histocompatibility antigen-disparate skin grafts. Roopenian DC; Anderson PS Transplantation; 1988 Dec; 46(6):899-904. PubMed ID: 2905088 [TBL] [Abstract][Full Text] [Related]
14. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. Benichou G; Valujskikh A; Heeger PS J Immunol; 1999 Jan; 162(1):352-8. PubMed ID: 9886406 [TBL] [Abstract][Full Text] [Related]
15. Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens. Sano Y; Ksander BR; Streilein JW Invest Ophthalmol Vis Sci; 1997 May; 38(6):1130-8. PubMed ID: 9152232 [TBL] [Abstract][Full Text] [Related]
16. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. Chen PW; Ananthaswamy HN J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126 [TBL] [Abstract][Full Text] [Related]
17. Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target alloantigen on Ia- epidermal cells. Rosenberg AS; Katz SI; Singer A J Immunol; 1989 Oct; 143(8):2452-6. PubMed ID: 2477443 [TBL] [Abstract][Full Text] [Related]
18. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier. Koch U; Choksi S; Marcucci L; Korngold R J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252 [TBL] [Abstract][Full Text] [Related]
19. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model. Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433 [TBL] [Abstract][Full Text] [Related]
20. Marked prolongation of incompatible class I deficient heart allografts: paradoxical effects between primarily and secondarily vascularized allografts. Henretta J; Araneda D; Pittman K; Thomas F Transplant Proc; 1995 Feb; 27(1):1303-4. PubMed ID: 7878892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]